

emyria

Delivering & developing new treatments for mental health & neurological conditions

ASX Announcement | 01 Jul 2024

Emyria and UWA Awarded $499,411 Innovation Grant to Advance Proprietary MDMA Analogue Program

HIGHLIGHTS

$499,411 grant received from the Future Health Research and Innovation Seed Fund to advance Emyria's MDMA analogue drug development program with the University of Western Australia [1]
Non-dilutive funds to directly support Emyria's mission developing, applying and testing new therapies for mental health and selected neurodegenerative diseases
Associate Prof. Matt Piggott, a leading expert on MDMA-inspired drug discovery, will direct the medicinal chemistry and screening program [2]
Initial funds to progress a world-leading program targeting the enhancement of Parkinson's disease treatment
Funds to facilitate international collaborations as well as support development of UWA-Emyria's second program focussed on potential new treatments for PTSD

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") focused on delivering and developing innovative treatments for mental health and select neurological conditions, is pleased to announce a $499,411 grant award from the Future Health Research and Innovation (FHRI) Seed Fund in partnership with the University of Western Australia (UWA).

Grant Purpose and Significance

The FHRI Seed Fund provides Western Australian innovators with non-dilutive funding to facilitate projects with high commercial potential. This grant will advance Emyria's novel MDMA analogue drug discovery pipeline with UWA over the next 18 months to help validate our drug optimisation pipeline and potentially identify a drug candidate for development and commercialisation.

Grant funds will be allocated to key screening assays and gold-standard animal models delivered by global collaborators, including the National Institutes of Health (NIH), to progres towards clinical studies.

Emyria's Unique Operating Model to Deliver Impact

Emyria is dedicated to the development of new treatments for mental health, particularly to address major unmet needs in psychological trauma, and select neurological conditions. The Company has established a unique operating model that delivers commercially viable clinical services and real patient impact in the short-term while fostering high potential innovation for long-term value.

Emyria's Unique Operating Model to Deliver Impact - cont'd

Recently, the Company established itself as one of the few clinical services, globally, with the expertise [3, 4], bespoke facilities [5] and regulatory approvals required to evaluate MDMA-assisted therapy for PTSD within the legal access pathways established by Australia's Therapeutic Goods Administration (TGA).

Since 2021, Emyria and UWA have been creating and evaluating a library of proprietary MDMA-like compounds as part of the Company's long-term drug discovery and development initiatives [6], establishing Emyria as a global leader in MDMA-related treatments.

Emyria's MDMA-inspired Drug Discovery with UWA

Emyria's drug discovery partnership with UWA has created a large, patented library of novel chemical entities that are structurally similar to MDMA but designed to elicit unique clinical and neuro-cognitive effects. These analogues have passed initial safety screens and have the potential to become novel and patentable treatments. The two leading drug discovery programs are:

- The enhancement and extension of levodopa therapy for Parkinson's disease (PD)
- The development of next-generation entactogens for drug-assisted psychotherapy

Parkinson's Disease

Parkinson's disease, one of the world's fastest growing neurological disorders affecting 10 million adults [7], is most commonly treated with the drug levodopa. MDMA extends the duration of levodopa treatment, and alleviates a debilitating side effect of this therapy: uncontrolled, involuntary movements called levodopa-induced dyskinesia (LID) [8]. However, MDMA's psychoactivity makes it unsuitable for daily use. The only existing drug to address LID (amantadine) has very modest efficacy, and is intolerable to many patients; hence there is a great unmet need.

A/Prof. Piggott's research has created a number of non-psychoactive MDMA analogues, and identified a drug lead (UWA-121) that outperforms clinical drugs in extending and enhancing levodopa therapy in laboratory models of LID [9]. UWA and Emyria have worked in partnership to generate a large library of patented analogues of UWA-121 (structurally similar compounds) that are being evaluated to optimise properties and identify a drug candidate for development.

MDMA-Assisted Psychotherapy

MDMA-assisted therapy is showing great potential for the treatment of PTSD. Nevertheless, there is interest in MDMA-like alternatives that can deliver the desirable and positive, prosocial effects of MDMA with shorter treatment sessions and with less potential for adverse events.

Emyria's drug discovery program with UWA has demonstrated that structural modifications can be achieved with MDMA that tailors interactions with key brain targets, and either increases or decreases metabolic stability (affecting duration of action)[10].

Michael Winlo, CEO: *"We are thrilled to receive this substantial grant from the West Australian Department of Health in partnership with UWA. This brings the amount of non-dilutive funding won this year to over $500k creating a significant boost for Emyria's long-term innovation pipeline and, along with our MDMA-assisted therapy evaluation program, helps reinforce our global leadership in MDMA-related treatment delivery and development."*

Developments Ahead for Remainder of 2024:

1. **National Phase Patent Filing:** Following a clear search report from the international patent examiner [11], indicating the novelty and potential patentability of its massive library of novel MDMA analogues, the Company has entered the National Filing phase in key markets.

2. **Definitive Commercial Licence Negotiation with UWA:** The Company has initiated formal licensing discussions to support commercialisation and market introduction of the analogues covered in the first patent family.

References:

1. https://www.uwa.edu.au/news/article/2024/june/wa-innovators-improving-health-and-medical-outcomes
2. https://research-repository.uwa.edu.au/en/persons/matthew-piggott
3. See ASX release 28 February 2024.
4. See ASX releases 10 January 2024 and 05 April 2024
5. See ASX release 10 April 2024
6. See ASX release 05 August 2021
7. https://www.parkinsons.org.au/statistics/
8. See ASX release 01 September 2021
9. Johnston,T et al *A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances l-DOPA benefit in parkinsonian primates* FASEB J. 26, 2154-2163 (2012)
10. See Company webinar, July 2023
11. See ASX release 10 April 2024

This release has been approved by the Board of Emyria.

For further information, investment opportunities, or more about our approach to mental health treatment, please contact:

Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com

Media Contact
Haley Chartres
+61 (0) 423 139 163
haley@hck.digital

Corporate Advisor
Sufian Ahmed
+61 (0) 412 316 162
info@62capital.com.au

emyria.com

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through through an integrated model of direct clinical services and drug development:

generates

Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD [1]

informs

Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients and used to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. These effects of MDMA are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision.